查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433535

肝转移治疗市场规模、份额、趋势分析报告：依治疗类型、原发癌症、通路、地区、细分市场预测，2024-2030

Liver Metastases Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Immunotherapy), By Primary Cancer, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

肝转移治疗市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球肝转移治疗市场预计将达到26.6亿美元，2024年至2030年复合年增长率为7.3%。

目标疾病盛行率的上升、开发中国家癌症的晚期诊断以及产品核可数量的增加预计将推动该行业的成长。

大肠、乳癌和肺癌是转移至肝臟的一些主要癌症类型。大肠发生率预计将从2020年的188万人增加到2030年的245万人。同时，乳癌发生率预计将从2020年的226万人增加到2030年的274万人。这些关键适应症的日益普及预计将推动市场成长。

低收入和中等收入国家的大多数癌症患者在诊断时已处于晚期，此时治疗方案较少。无法取得早期诊断方法和诊断报销情况不确定是诊断延误的主要原因。诊断的晚期/转移阶段为该领域提供了利润丰厚的成长机会。

另一方面，特别是在开发中国家和中低收入国家，由于缺乏产品和足够的报销，即使在癌症晚期才被诊断出来，晚期治疗率也明显较低。预计这些因素将抑制市场成长。

肝转移治疗市场报告亮点

  • 从治疗类型来看，标靶治疗市场主导地位，其核准的药物价格高于常规化疗，市占率为56.52%。
  • 2023年，大肠直肠癌以40.55%的份额主导肝转移治疗市场。约 25-30% 的大肠转移至肝臟。 CCLM 的各种治疗方案的可用性进一步增强了该细分市场的主导地位。
  • 从分销管道来看，医院药房细分市场占据主导地位，2023年份额为60.07%。肝转移治疗的高住院率是导致该细分市场占据主导地位的主要因素之一。
  • 按地区划分，2023年北美将在全球肝转移治疗市场中占据最高收益占有率。然而，亚太地区预计将成为预测期内成长最快的地区。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章肝转移治疗市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
  • 治疗类型普及与成长前景图，2023 年
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 市场分析工具
    • 产业分析：波特五力分析
    • 产业分析：PESTEL

第 4 章 肝转移治疗市场：2018-2030 年按治疗类型細項分析（百万美元）

  • 肝转移治疗市场：治疗类型变化分析

第五章肝转移治疗市场：依原发癌症細項分析，2018-2030（百万美元）

  • 肝转移治疗市场：原发癌症变化分析

第六章 肝转移治疗市场：依销售管道細項分析，2018-2030（百万美元）

  • 肝转移治疗市场：通路波动分析

第七章肝转移治疗市场：按类型、产品和应用分類的区域估计和趋势分析

  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲 (MEA)

第八章 竞争形势

  • 主要市场参与企业的最新趋势和影响分析
    • New product launch
    • Merger and acquisition
    • Licensing agreements
    • Conferences and campaigns
  • 公司分类
    • 创新者
    • 市场领导者
  • 供应商形势
    • List of key distributors and channel partners
    • Key customers
  • 上市公司
    • 2023年主要企业市场占有率分析
    • 公司市场分析
    • 热图分析
    • 竞争仪表板分析
  • 私人公司
    • 主要新兴企业名单
    • 区域网路图
  • 公司简介
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca
    • Bayer AG
    • Eli Lilly and Company
    • Ono Pharmaceutical
    • Pfizer, Inc.
    • Bristol-Myers Squibb Company
    • Cadila Pharmaceuticals Ltd.
Product Code: GVR-4-68040-034-2

Liver Metastases Treatment Market Growth & Trends:

The global liver metastases treatment market is expected to reach USD 2.66 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.3% from 2024 to 2030. Rising prevalence of target disease, advanced stage diagnosis for cancer in developing countries, and increasing number of products approvals is expected to drive the industry growth.

Colorectal cancer, breast cancer, and lung cancer are some of the key types that metastasize to the liver. The incidence of colorectal cancer is expected to increase from 1.88 million in 2020 to 2.45 million in 2030. Whereas the incidence of breast cancer is expected to increase from 2.26 million in 2020 to 2.74 million in 2030. The rising incidence of these primary indications is expected to drive space growth.

Majority of the cancer cases in low and middle-income countries are diagnosed at advanced stages where the availability of therapeutic options is low. The lack of availability of early diagnostics methods combined with uncertain reimbursement scenario for diagnostics are major reasons for delayed diagnosis. The advanced/metastatic stage of diagnosis provide lucrative growth opportunities in this space.

On the other hand, if cancers are diagnosed at advanced stages particularly in developing nations and LMICS, the treatment rate at such advanced stages is significantly less, due to unavailability of products and proper reimbursement. This factor is expected to restrain space growth.

Liver Metastases Treatment Market Report Highlights:

  • By treatment type, the targeted therapy segment dominated the market with a share of 56.52% to the presence of approved drugs with a price higher than traditional chemotherapy.
  • In 2023, colorectal cancer dominated the liver metastases treatment market with a share of 40.55%. Around 25-30% of all colorectal cancers metastasize to the liver. The availability of various treatment options for CCLM further contributed to the segments' dominance.
  • Based on distribution channel, the market was dominated by the hospital pharmacies segment with a share of 60.07% in 2023. The high rate of hospitalization for the treatment of liver metastases is one of the major factors for the dominance of this segment.
  • By region, North America has a high revenue share in the global liver metastases treatment market in 2023. However, Asia Pacific is expected to be the fastest growing region during the forecast period.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Regional scope
    • 1.1.2 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity flow analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity flow approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Landscape Snapshot

Chapter 3 Liver Metastases treatment Market Variables, Trends, and Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market outlook
      • 3.1.1.1 Liver cancer treatment market
  • 3.2 Penetration and Growth Prospect Mapping for Treatment Type, 2023
  • 3.3 Market Dynamics
    • 3.3.1 Market driver analysis
      • 3.3.1.1 Approval of targeted therapy for the treatment of liver metastases
    • 3.3.2 Market restraint analysis
      • 3.3.2.1 Technological advancements for early diagnosis of cancer
  • 3.4 Market Analysis Tools
    • 3.4.1 Industry analysis: porter's
      • 3.4.1.1 Threat of new entrants
      • 3.4.1.2 Bargaining power of buyers
      • 3.4.1.3 Competitive rivalry
      • 3.4.1.4 Threat of substitutes
      • 3.4.1.5 Bargaining power of suppliers
    • 3.4.2 Industry analysis: PESTEL
      • 3.4.2.1 Political & Legal
      • 3.4.2.2 Economical
      • 3.4.2.3 Technological

Chapter 4 Liver Metastases treatment Market: Segment Analysis, by Treatment Type, 2018 - 2030 (USD Million)

  • 4.1 Liver Metastases treatment Market: Treatment Type Movement Analysis
    • 4.1.1 Chemotherapy
      • 4.1.1.1 Chemotherapy market estimates and forecast, 2018 - 2030 (USD million)
    • 4.1.2 Targeted Therapy
      • 4.1.2.1 Targeted therapy market estimates and forecast, 2018 - 2030 (USD million)
    • 4.1.3 Immunotherapy
      • 4.1.3.1 Immunotherapy market estimates and forecast, 2018 - 2030 (USD million)

Chapter 5 Liver Metastases Treatment Market: Segment Analysis, by Primary Cancer, 2018 - 2030 (USD Million)

  • 5.1 Liver Metastases treatment Market: Primary Cancer Movement Analysis
    • 5.1.1 Colorectal cancer
      • 5.1.1.1 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD million)
    • 5.1.2 Breast Cancer
      • 5.1.2.1 Breast cancer market estimates and forecast, 2018 - 2030 (USD million)

Chapter 6 Liver Metastases treatment Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

  • 6.1 Liver Metastases treatment Market: Distribution Channel Movement Analysis
    • 6.1.1 Hospital Pharmacies
      • 6.1.1.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD million)
    • 6.1.2 Specialty pharmacies
      • 6.1.2.1 Specialty pharmacies market estimates and forecast, 2018 - 2030 (USD million)

Chapter 7 Liver Metastases treatment Market: Regional Estimates and Trend Analysis, by Type, Product, & Application

  • 7.1 North America
    • 7.1.1 SWOT analysis
      • 7.1.1.1 North america liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.1.2 U.S.
      • 7.1.2.1 Key country dynamics
      • 7.1.2.2 Target disease prevalence
      • 7.1.2.3 Competitive scenario
      • 7.1.2.4 Regulatory framework
      • 7.1.2.5 Reimbursement scenario
      • 7.1.2.6 U.S. Liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.1.3 Canada
      • 7.1.3.1 Key country dynamics
      • 7.1.3.2 Target disease prevalence
      • 7.1.3.3 Competitive scenario
      • 7.1.3.4 Regulatory framework
      • 7.1.3.5 Reimbursement scenario
      • 7.1.3.6 Canada liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2 Europe
    • 7.2.1 SWOT analysis:
      • 7.2.1.1 Europe liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.2 Germany
      • 7.2.2.1 Key country dynamics
      • 7.2.2.2 Target disease prevalence
      • 7.2.2.3 Competitive scenario
      • 7.2.2.4 Regulatory framework
      • 7.2.2.5 Reimbursement scenario
      • 7.2.2.6 Germany Liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.3 UK
      • 7.2.3.1 Key country dynamics
      • 7.2.3.2 Target disease prevalence
      • 7.2.3.3 Competitive scenario
      • 7.2.3.4 Regulatory Framework
      • 7.2.3.5 Reimbursement Scenario
      • 7.2.3.6 UK liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.4 France
      • 7.2.4.1 Key country dynamics
      • 7.2.4.2 Target disease prevalence
      • 7.2.4.3 Competitive scenario
      • 7.2.4.4 Regulatory framework
      • 7.2.4.5 Reimbursement scenario
      • 7.2.4.6 France liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.5 Italy
      • 7.2.5.1 Key country dynamics
      • 7.2.5.2 Target disease prevalence
      • 7.2.5.3 Competitive scenario
      • 7.2.5.4 Regulatory framework
      • 7.2.5.5 Reimbursement scenario
      • 7.2.5.6 Italy liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.6 Spain
      • 7.2.6.1 Key country dynamics
      • 7.2.6.2 Target disease prevalence
      • 7.2.6.3 Competitive scenario
      • 7.2.6.4 Regulatory framework
      • 7.2.6.5 Reimbursement scenario
      • 7.2.6.6 Spain liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.7 Denmark
      • 7.2.7.1 Key country dynamics
      • 7.2.7.2 Target disease prevalence
      • 7.2.7.3 Competitive scenario
      • 7.2.7.4 Regulatory framework
      • 7.2.7.5 Reimbursement scenario
      • 7.2.7.6 Denmark liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.8 Sweden
      • 7.2.8.1 Key country dynamics
      • 7.2.8.2 Target disease prevalence
      • 7.2.8.3 Competitive scenario
      • 7.2.8.4 Regulatory framework
      • 7.2.8.5 Reimbursement scenario
      • 7.2.8.6 Sweden liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.2.9 Norway
      • 7.2.9.1 Key country dynamics
      • 7.2.9.2 Target disease prevalence
      • 7.2.9.3 Competitive scenario
      • 7.2.9.4 Regulatory framework
      • 7.2.9.5 Reimbursement scenario
      • 7.2.9.6 Norway liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3 Asia Pacific
    • 7.3.1 SWOT analysis:
      • 7.3.1.1 Asia Pacific liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.3.2 Japan
      • 7.3.2.1 Key country dynamics
      • 7.3.2.2 Target disease prevalence
      • 7.3.2.3 Competitive scenario
      • 7.3.2.4 Regulatory framework
      • 7.3.2.5 Reimbursement scenario
      • 7.3.2.6 Japan liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.3.3 China
      • 7.3.3.1 Key country dynamics
      • 7.3.3.2 Target disease prevalence
      • 7.3.3.3 Competitive scenario
      • 7.3.3.4 Regulatory framework
      • 7.3.3.5 Reimbursement scenario
      • 7.3.3.6 China liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.3.4 India
      • 7.3.4.1 Key country dynamics
      • 7.3.4.2 Target disease prevalence
      • 7.3.4.3 Competitive scenario
      • 7.3.4.4 Regulatory framework
      • 7.3.4.5 Reimbursement scenario
      • 7.3.4.6 India liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.3.5 Australia
      • 7.3.5.1 Key country dynamics
      • 7.3.5.2 Target disease prevalence
      • 7.3.5.3 Competitive scenario
      • 7.3.5.4 Regulatory framework & reimbursement scenario
      • 7.3.5.5 Australia liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.3.6 Thailand
      • 7.3.6.1 Key country dynamics
      • 7.3.6.2 Target disease prevalence
      • 7.3.6.3 Competitive scenario
      • 7.3.6.4 Regulatory framework & reimbursement scenario
      • 7.3.6.5 Thailand liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.3.7 South Korea
      • 7.3.7.1 Key country dynamics
      • 7.3.7.2 Target disease prevalence
      • 7.3.7.3 Competitive scenario
      • 7.3.7.4 Regulatory framework & reimbursement scenario
      • 7.3.7.5 South Korea liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.4 Latin America
    • 7.4.1 SWOT analysis:
      • 7.4.1.1 Latin America liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.4.2 Brazil
      • 7.4.2.1 Key country dynamics
      • 7.4.2.2 Target disease prevalence
      • 7.4.2.3 Competitive scenario
      • 7.4.2.4 Regulatory framework
      • 7.4.2.5 Reimbursement scenario
      • 7.4.2.6 Brazil liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.4.3 Mexico
      • 7.4.3.1 Key country dynamics
      • 7.4.3.2 Target disease prevalence
      • 7.4.3.3 Competitive scenario
      • 7.4.3.4 Regulatory framework
      • 7.4.3.5 Reimbursement scenario
      • 7.4.3.6 Mexico liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.4.4 Argentina
      • 7.4.4.1 Key country dynamics
      • 7.4.4.2 Target disease prevalence
      • 7.4.4.3 Competitive scenario
      • 7.4.4.4 Regulatory framework
      • 7.4.4.5 Reimbursement scenario
      • 7.4.4.6 Argentina liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.5 Middle East & Africa (MEA)
    • 7.5.1 SWOT analysis:
      • 7.5.1.1 Middle East & Africa liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.5.2 South Africa
      • 7.5.2.1 Key Country dynamics
      • 7.5.2.2 Target disease prevalence
      • 7.5.2.3 Competitive scenario
      • 7.5.2.4 Regulatory framework
      • 7.5.2.5 Reimbursement scenario
      • 7.5.2.6 South Africa liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.5.3 Saudi Arabia
      • 7.5.3.1 Key country dynamics
      • 7.5.3.2 Target disease prevalence
      • 7.5.3.3 Competitive scenario
      • 7.5.3.4 Regulatory framework
      • 7.5.3.5 Reimbursement scenario
      • 7.5.3.6 Saudi Arabia liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.5.4 UAE
      • 7.5.4.1 Key country dynamics
      • 7.5.4.2 Target disease prevalence
      • 7.5.4.3 Competitive scenario
      • 7.5.4.4 Regulatory framework
      • 7.5.4.5 Reimbursement scenario
      • 7.5.4.6 UAE liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.5.5 Kuwait
      • 7.5.5.1 Key country dynamics
      • 7.5.5.2 Target disease prevalence
      • 7.5.5.3 Competitive scenario
      • 7.5.5.4 Regulatory framework
      • 7.5.5.5 Reimbursement Scenario
      • 7.5.5.6 Kuwait liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
      • 7.5.5.7 Rest of MEA liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)

Chapter 8 Competitive Landscape

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 8.1.1 New product launch
    • 8.1.2 Merger and acquisition
    • 8.1.3 Licensing agreements
    • 8.1.4 Conferences and campaigns
  • 8.2 Company Categorization
    • 8.2.1 Innovators
    • 8.2.2 Market leaders
  • 8.3 Vendor Landscape
    • 8.3.1 List of key distributors and channel partners
    • 8.3.2 Key customers
  • 8.4 Public Companies
    • 8.4.1 Key company market share analysis, 2023
    • 8.4.2 Company market position analysis
    • 8.4.3 Heat map analysis
    • 8.4.4 Competitive dashboard analysis
      • 8.4.4.1 Market differentiators
  • 8.5 Private Companies
    • 8.5.1 List of key emerging companies
    • 8.5.2 Regional network map
  • 8.6 Company Profiles
    • 8.6.1. F. Hoffmann-La Roche Ltd.
      • 8.6.1.1 Company overview
      • 8.6.1.2 Financial performance
      • 8.6.1.3 Product benchmarking
      • 8.6.1.4 Strategic initiatives
    • 8.6.2 AstraZeneca
      • 8.6.2.1 Company overview
      • 8.6.2.2 Financial performance
      • 8.6.2.3 Product benchmarking
      • 8.6.2.4 Strategic initiatives
    • 8.6.3 Bayer AG
      • 8.6.3.1 Company overview
      • 8.6.3.2 Financial performance
      • 8.6.3.3 Product benchmarking
      • 8.6.3.4 Strategic initiatives
    • 8.6.4 Eli Lilly and Company
      • 8.6.4.1 Company overview
      • 8.6.4.2 Financial performance
      • 8.6.4.3 Product benchmarking
      • 8.6.4.4 Strategic initiatives
    • 8.6.5 Ono Pharmaceutical
      • 8.6.5.1 Company overview
      • 8.6.5.2 Financial performance
      • 8.6.5.3 Product benchmarking
      • 8.6.5.4 Strategic initiatives
    • 8.6.6 Pfizer, Inc.
      • 8.6.6.1 Company overview
      • 8.6.6.2 Financial performance
      • 8.6.6.3 Product benchmarking
      • 8.6.6.4 Strategic initiatives
    • 8.6.7 Bristol-Myers Squibb Company
      • 8.6.7.1 Company overview
      • 8.6.7.2 Financial performance
      • 8.6.7.3 Product benchmarking
      • 8.6.7.4 Strategic initiatives
    • 8.6.8 Cadila Pharmaceuticals Ltd.
      • 8.6.8.1 Company overview
      • 8.6.8.2 Financial performance
      • 8.6.8.3 Product benchmarking
      • 8.6.8.4 Strategic initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Liver Metastases Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 6 Global Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 7 Global Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 North America Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 9 North America Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 10 North America Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 11 North America Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 14 U.S. Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Canada Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 17 Canada Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 Europe Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 19 Europe Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 20 Europe Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 21 Europe Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 Germany Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 23 Germany Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 24 Germany Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 UK Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 26 UK Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 27 UK Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 France Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 29 France Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 30 France Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Italy Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 32 Italy Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 33 Italy Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Spain Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 35 Spain Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 36 Spain Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Denmark Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 38 Denmark Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 39 Denmark Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Sweden Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 41 Sweden Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 42 Sweden Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Norway Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 44 Norway Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 45 Norway Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Japan Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 51 Japan Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 52 Japan Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 China Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 54 China Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 55 China Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 India Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 57 India Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 58 India Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 South Korea Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 61 South Korea Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Australia Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 63 Australia Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 64 Australia Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Thailand Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 66 Thailand Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 67 Thailand Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Latin America Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 69 Latin America Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 70 Latin America Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 71 Latin America Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 Brazil Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 73 Brazil Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 74 Brazil Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 75 Mexico Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 76 Mexico Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 77 Mexico Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 78 Argentina Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 80 Argentina Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Liver Metastases Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 84 Middle East & Africa Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 South Africa Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 89 South Africa Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 90 South Africa Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 91 UAE Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 92 UAE Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 93 UAE Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Liver Metastases Treatment Market, By Treatment Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Liver Metastases Treatment Market, By Primary Cancer, 2018 - 2030 (USD Million)
  • Table 96 Kuwait Liver Metastases Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Liver Metastases Treatment Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Information Procurement
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 QFD Modeling For Market Share Assessment
  • Fig. 8 Market Formulation & Validation
  • Fig. 9 Market Snapshot
  • Fig. 10 Segment Snapshot (By Treatment Type, By Primary Cancer, And By Distribution Channel)
  • Fig. 11 Competitive Landscape Snapshot
  • Fig. 12 Penetration & Growth Prospect Mapping For Type, 2023
  • Fig. 13 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 14 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 15 Liver Metastases Treatment Market: Treatment Type Outlook And Key Takeaways
  • Fig. 16 Liver Metastases Treatment Market: Treatment Type Movement Analysis
  • Fig. 17 Chemotherapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Targeted Therapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Immunotherapy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Liver Metastases Treatment Market: Primary Cancer Outlook And Key Takeaways
  • Fig. 21 Liver Metastases Treatment Market: Primary Cancer Movement Analysis
  • Fig. 22 Colorectal Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Breast Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Liver Metastases Treatment Market: Distribution Channel Outlook And Key Takeaways
  • Fig. 26 Liver Metastases Treatment Market: Distribution Channel Movement Analysis
  • Fig. 27 Hospital Pharmacies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Hospital Pharmacies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Regional Marketplace: Key Takeaways
  • Fig. 30 North America: SWOT Analysis
  • Fig. 31 North America Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Key Country Dynamics
  • Fig. 33 U.S. Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 34 U.S. Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Canada Key Country Dynamics
  • Fig. 36 Canada Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 37 Canada Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe: SWOT Analysis
  • Fig. 39 Europe Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany Key Country Dynamics
  • Fig. 41 Germany Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 42 Germany Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 UK Key Country Dynamics
  • Fig. 44 UK Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 45 UK Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 France Key Country Dynamics
  • Fig. 47 France Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 48 France Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Key Country Dynamics
  • Fig. 50 Italy Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 51 Italy Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Spain Key Country Dynamics
  • Fig. 53 Spain Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 54 Spain Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Denmark Key Country Dynamics
  • Fig. 56 Denmark Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 57 Denmark Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Sweden Key Country Dynamics
  • Fig. 59 Sweden Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 60 Sweden Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Norway Key Country Dynamics
  • Fig. 62 Norway Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 63 Norway Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Asia Pacific: SWOT Analysis
  • Fig. 65 Asia Pacific Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Japan Key Country Dynamics
  • Fig. 67 Japan Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 68 Japan Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 China Key Country Dynamics
  • Fig. 70 China Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 71 China Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 India Key Country Dynamics
  • Fig. 73 India Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 74 India Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Australia Key Country Dynamics
  • Fig. 76 Australia Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 77 Australia Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 South Korea Key Country Dynamics
  • Fig. 79 South Korea Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 80 South Korea Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Thailand Key Country Dynamics
  • Fig. 82 Thailand Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 83 Thailand Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Latin America (LATAM): SWOT Analysis
  • Fig. 85 Latin America Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Brazil Key Country Dynamics
  • Fig. 87 Brazil Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 88 Brazil Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Mexico Key Country Dynamics
  • Fig. 90 Mexico Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 91 Mexico Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Argentina Key Country Dynamics
  • Fig. 93 Argentina Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 94 Argentina Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Middle East & Africa (MEA): SWOT Analysis
  • Fig. 96 Middle East & Africa (MEA) Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 South Africa Key Country Dynamics
  • Fig. 98 Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 99 South Africa Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Saudi Arabia Key Country Dynamics
  • Fig. 101 Saudi Arabia Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 102 Saudi Arabia Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 UAE Key Country Dynamics
  • Fig. 104 UAE Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 105 UAE Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Kuwait Key Country Dynamics
  • Fig. 107 Kuwait Target Disease Prevalence (Patient Volume) ('000), 2018 - 2030
  • Fig. 108 Kuwait Liver Metastases Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Heat Map Analysis
  • Fig. 110 Strategic Framework